Mostrar el registro sencillo del ítem

Treatment Response to Hydroxychloroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First Report on the Pharmacological Outcomes from South Korea

dc.contributor.authorKim, Min Seo et al.
dc.date.accessioned2020-06-15T19:02:26Z
dc.date.available2020-06-15T19:02:26Z
dc.date.issued2020-06-14
dc.identifier.urihttps://doi.org/10.1101/2020.05.13.20094193en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12663/1750
dc.description.abstractThe authors have withdrawn this manuscript because of the controversy about hydroxychloroquine and potential changes in results after peer-review, the authors intend to share their results in formal publication. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.en_US
dc.languageEnglishen_US
dc.subjectCOVID-19en_US
dc.subjectCoronavirusen_US
dc.subjectHydroxychloroquineen_US
dc.subjectLopinaviren_US
dc.subjectRitonaviren_US
dc.subjectAnti-Bacterial Agentsen_US
dc.subjectCoronavirus Infectionsen_US
dc.subjectDrug Therapyen_US
dc.titleTreatment Response to Hydroxychloroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First Report on the Pharmacological Outcomes from South Koreaen_US
eihealth.countryGlobal (WHO/OMS)en_US
eihealth.categoryCandidate therapeutics RDen_US
eihealth.typePublished Articleen_US
eihealth.maincategorySave Lives / Salvar Vidasen_US
dc.relation.ispartofjournalmedRxiven_US


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem